Archive
The National Cancer Institute periodically highlights a particular trial or group of trials out of more than 150 available cancer clinical trials conducted at the National Institutes of Health in Bethesda, Maryland. Below you will find the archived list of previous Clinical Trial Spotlights:
Archived Clinical Trial Spotlights
Clinical Trials—Dr. Itzhak Avital
- Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
NCI-09-C-0189 - The Natural History of Solid Organ Cancer Stem Cells
NCI-09-C-0079
Clinical Trial—Dr. Jay A. Berzofsky
- A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
NCI-09-C-0139
Clinical Trials—Dr. Michael Bishop
- Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes
NCI-07-C-0064 - T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors for Hematologic Malignancies
NCI-04-C-0116
Clinical Trial—Dr. Kevin Camphausen
- A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas
NCI-06-C-0112
Clinical Trials—Deborah Citrin
- A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligometastases
NCI-07-C-0230 - A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies
NCI-07-C-0111
Clinical Trial—Dr. Edward Cowen
Clinical Trials—Dr. William Dahut
- A Phase II Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
NCI-09-C-0195 - A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen-Independent Prostate Cancer (APIC)
NCI-08-C-0074 - A Phase II Study of AZD2171 in Metastatic Androgen-Independent Prostate Cancer
NCI-07-C-0059 - A Phase II Study of Docetaxel, Thalidomide, Prednisone, and Bevacizumab in Patients With Metastatic Androgen-Independent Prostate Cancer
NCI-04-C-0257
Clinical Trials—Dr. Phillip Dennis
- A Phase I/II Trial of Pemetrexed (Alimta®) Combined With Sirolimus (Rapamycin, Rapamune®) in Subjects With Relapsed or Refractory NSCLC Whose Tumors Bear Activation of mTOR
NCI-08-C-0078 - A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
NCI-07-C-0047
Clinical Trial—Dr. James Doroshow
- A Phase I Trial of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
NCI-06-C-0221
Clinical Trial—Dr. Kieron Dunleavy
- A Phase I/II Study of Flavopiridol in Relapsed or Refractory Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
NCI-07-C-0081
Clinical Trials—Dr. Howard Fine
- A Phase II Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas
NCI-08-C-0101 - A Phase II Trial of Enzastaurin (LY317615) in Combination With Bevacizumab in Adults With Recurrent Malignant Gliomas
NCI-08-C-0015 - A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
NCI-07-C-0053 - Phase II Trial of Bevacizumab for Patients With Recurrent High-Grade
Gliomas
NCI-06-C-0064 - Phase I/II Study of ZD6474 in Patients With Recurrent High-Grade or Progressive Low-Grade Gliomas
NCI-06-C-0063 - A Phase II Trial of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas
NCI-05-C-0137 - A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative
NCI-02-C-0140 - Evaluation of the Natural History of Patients With Tumors of the Central Nervous System
NCI-01-C-0070
Clinical Trial—Dr. Antonio Tito Fojo
- A Phase II Clinical Trial of BMS-247550 (NSC 710428), an Epothilone B Analog, in Renal Cell Carcinoma
NCI-02-C-0130
Clinical Trial—Dr. Daniel Fowler
- Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome
NCI-04-C-0055
Clinical Trials—Dr. Elizabeth Fox
- A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS®, ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors
NCI-07-C-0054 - Phase I Trial of Cediranib (AZ2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors or Acute Myelogenous Leukemia
NCI-06-C-0152
Clinical Trials—Dr. Giuseppe Giaccone
- Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
NCI-09-C-0212 - Phase II Study of Neoadjuvant Gemcitabine, Cisplatin, and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer
NCI-09-C-0107 - Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
NCI-09-C-0103 - A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Adults With Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Two or More Prior Treatment Regimens
NCI-09-C-0018 - Pilot Trial of Pioglitazone in Patients Undergoing Surgical Resection of Non-Small Cell Lung Cancer
NCI-08-C-0208 - A Phase II, Open-Label, Two Arm Trial to Evaluate the Efficacy of PF-00299804 in Patients With Advanced NSCLC After Failure of at Least One Prior Chemotherapy Regime and Failure of Prior Treatment With Erlotinib
NCI-08-C-0086 - Registration Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-Small Cell Lung Cancer: An International Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Lucanix™ Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-Line, Platinum-Based Combination Chemotherapy
NCI-08-C-0083 - Multicenter Phase II Study of Belinostat (PXD101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma
NCI-08-C-0033
Clinical Trial—Dr. Ronald Gress
- Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults
NCI-08-C-0097
Clinical Trials—Dr. James Gulley
- An Open-Label Phase I Study to Evaluate the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-Expressing Carcinoma
NCI-09-C-0101 - An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults With Non-Small Cell Lung Cancer (NSCLC)
NCI-08-C-0166 - A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer
NCI-07-C-0107 - A Randomized Phase 2.5 Study of 153Sm-EDTMP (Quadramet) With or Without a PSA TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer
NCI-07-C-0106 - A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC -V (vaccinia) and PANVAC-F (fowlpox) in Patients With Metastatic Breast Cancer
NCI-05-C-0229
Clinical Trials—Dr. Raffit Hassan
- An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
NCI-09-C-0077 - Phase I, Single Center, Dose-Escalation Study of SS1(dsFv)-PE38 Administered Concurrently With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Epithelial Pleural Mesothelioma
NCI-08-C-0026
Clinical Trial—Dr. Dennis Hickstein
- Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMac
NCI-09-C-0096
Clinical Trials—Dr. John Janik
- Phase I Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T- and NK-Cell Lymphomas
NCI-09-C-0065 - Microarray Analysis of the Effect of Cyclosporine Therapy on Gene Expression Patterns in Large Granular Lymphocytic Leukemia
NCI-06-C-0177 - Phase II Study of the Efficacy and Toxicity of Ontak® (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
NCI-05-C-0185 - A Pilot Study of MDX-CTLA-4 in Lymphoma
NCI-02-C-0284 - A Phase I Investigation of IL-12/Pulse IL-2 in Adults With Advanced Solid Tumors
NCI-00-C-0121
Clinical Trials—Dr. Aradhana Kaushal
- Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation With Intensity Modulated Radiation Therapy (IMRT)
NCI-05-C-0241 - Phase I Study of Image Guided Dose Escalation With Intensity Modulated Radiation Therapy (IMRT) to Histologically Confirmed Regions of Prostate Cancer
NCI-05-C-0191
Clinical Trials—Dr. Elise Kohn
- A Phase I, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Refractory Solid Tumors Associated With EphA2 Expression
NCI-09-C-0168 - A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
NCI-09-C-0019 - A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined With Carboplatin in Breast and Ovarian Cancer in BRCA 1/2 Mutation Carriers and Familial Breast and Ovarian Cancer
NCI-08-C-0092 - A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer
NCI-07-C-0058
Clinical Trial—Dr. Teri Kreisl
Clinical Trials—Dr. Robert Kreitman
- Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia (HCL)
NCI-09-C-0076 - Phase II Trial of LMB-2, Fludarabine, and Cyclophosphamide for Adult T-Cell Leukemia
NCI-09-C-0025 - Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease
NCI-09-C-0005 - A Phase I, Multicenter, Dose-Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Hairy Cell Leukemia
NCI-07-C-0130 - Phase II Study of LMB-2 Immunotoxin in Patients With Recurrent or Refractory CD25-Positive Hairy Cell Leukemia
NCI-06-C-0150 - A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Cutaneous T-Cell Lymphomas
NCI-04-C-0142 - Phase II Study of LMB-2 Immunotoxin in Patients With CD25-Positive Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
NCI-04-C-0121
Clinical Trials—Dr. Shivaani Kummar
- Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
NCI-09-C-0192 - A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors
NCI-09-C-0138 - Multi-Institutional Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
NCI-06-C-0227 - A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux®) in EGFR Expressing Metastatic Colorectal Cancer (CRC)
NCI-06-C-0164 - A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1alpha
NCI-05-C-0186
Clinical Trial—Dr. W. Marston Linehan
- A Phase II Study of ZD6474 (Vandetanib) in Subjects With Advanced Clear Cell Renal Carcinoma
NCI-08-C-0039
Clinical Trials—Dr. John Morris
- A Phase I Study of the Safety and Efficacy of GC1008: A Human Anti-Transforming Growth Factor-beta (TGF-ß) Monoclonal Antibody in Patients With Advanced Renal Cell Carcinoma or Malignant Melanoma
NCI-06-C-0200 - A Phase I Open-Label Single-Dose Study of Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R{beta} Subunit (CD122) in T-Cell Large Granular Lymphocytic Leukemia
NCI-04-C-0089 - A Phase I/II Study of an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer
NCI-04-C-0049 - Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax®) in the Therapy of Tac-Expressing Adult T-Cell Leukemia
NCI-00-C-0030
Clinical Trial—Dr. Steven Pavletic
- Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients With Chronic Graft-Versus-Host Disease (GVHD)
NCI-04-C-0281
Clinical Trial—Dr. Richard Piekarz
- Phase I Trial of Romidepsin (Depsipeptide) Given on Days One, Three and Five in Patients With Thyroid and Other Advanced Cancers
NCI-03-C-0030
Clinical Trials—Dr. Steven Rosenberg
- Phase I/II Study of B-Cell Malignancies Using T Cells Expressing an Anti-DC19 Chimeric Receptor: Assessment of the Impact of Lymphocyte Depletion Prior to T-Cell Transfer
NCI-09-C-0082 - Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines
NCI-09-C-0051 - Phase II Study of Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes
NCI-09-C-0047 - Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
NCI-08-C-0121 - Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization
NCI-08-C-0055 - Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes
NCI-07-C-0175 - Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High Risk Melanoma
NCI-06-C-0069
Clinical Trials—Dr. David Schrump
- Prospective Evaluation of Epigenetic Alterations in Patients With Thoracic Malignancies
NCI-06-C-0014 - Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion in Patients With Malignancies Involving Lungs, Esophagus, or Pleura
NCI-05-C-0010
Clinical Trial—Dr. Claude Sportès
- A Phase I-II Study of Tumor Vaccine Following Chemotherapy in Patients With Metastatic Breast Cancer Untreated With Chemo/Radiation in the Previous 18 Months: Vaccine-Induced Bias of T-Cell Repertoire Reconstitution After T-Cell Re-Infusion
NCI-03-C-0040
Clinical Trial—Dr. Ramaprasad Srinivasan
- A Phase II Study of the c-Met RTK Inhibitor GSK 1363089 (Formerly XL880) in Subjects With Papillary Renal-Cell Carcinoma (PRC)
NCI-07-C-0121
Clinical Trial—Dr. Katherine Warren
- Comparative Trial of Pediatric CNS Tumor Activity as Assessed by PET Imaging and Proton Magnetic Resonance Spectroscopy Imaging (MRSI)
NCI-03-C-0278
Clinical Trials—Dr. Brigitte Widemann
- Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Cancer
NCI-07-C-0189 - Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors
NCI-06-C-0043 - Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias
NCI-02-C-0031
Clinical Trials—Dr. Wyndham Wilson
- A Phase I/IIa Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
NCI-07-C-0006 - Phase III Randomized Study of R-CHOP Versus Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
NCI-05-C-0252 - Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics
NCI-05-C-0170 - Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas
NCI-04-C-0173 - Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
NCI-01-C-0030 - Treatment and Natural History Study of Lymphomatoid Granulomatosis
NCI-94-C-0074 - Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma
NCI-93-C-0133
Back to Top
